EFPIA : European Sunshine Act for Pharmaceutical Companies

The EFPIA Code on the Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations received its formal approval at the general assembly on 24-25 June 2013; it is required to be transposed into national Codes by 31 December 2013. There are 3 levels of disclosure established: Aggregate, Individual HCO and Individual HCP: At an aggregate level : everything concerning clinical trials (phase 1 to 4) for donations and grants, sponsorships, events & hospitality and fees for services & consultancy. For individual HCO : Donations & Grants, Sponsorships, events & hospitality: registration fees; travel & accommodation; …

Read More »

EFPIA | Pharmaceutical Companies to Disclose All Financial Relations with Healthcare Professionals

Brussels – July 2, 2013 – The European Federation of Pharmaceutical Industries and Associations (EFPIA) announced today the release of its disclosure code of transfers of value to healthcare professionals and organisations. The code requires all members of EFPIA to disclose transfers of value to HCP’s and HCO’s as of 2016 regarding all transfers in 2015. EFPIA is committed to introducing greater transparency around industry’s interactions with HCP’s and HCO’s. As an industry, we understand the need to provide a well-managed framework for collaboration for these relations to be as transparent as possible. Our industry’s collaboration with healthcare professionals requires …

Read More »

Les exigences de transparence des liens d’intérêt de l’EFPIA

En Avril 2013, les laboratoires pharmaceutiques britanniques ont, pour la première fois, publié le montant total de leurs relations financières avec les professionnels de santé (voir l’article concernant les publications de l’ABPI). Cette initiative s’intègre dans la tendance mondiale vers davantage de transparence, avec la publication récente de la version finale du Sunshine Act aux Etats-Unis et le « Disclosure Code » de l’EFPIA en Europe. Richard Bergström, Directeur de l’EFPIA, a récemment souligné l’importance des deux types de transparence à prendre en compte, la transparence des données (essais cliniques) et la transparence des relations avec les professionnels de santé. …

Read More »